This article is sponsored content brought to you by Dermacare-Vet.
Once weekly treatment for allergic skin disease in dogs
Dermcare’s new prescription product, Barazone®, is a novel topical therapy for the symptomatic treatment of Canine Atopic Dermatitis, contact allergy and other pruritic conditions of the dog. The active ingredient is budesonide, a glucocorticoid, formulated in a leave-on conditioner base.
Canine Atopic Dermatitis
Canine atopic dermatitis is one of the most common inflammatory and allergic skin diseases in dogs. It is described as a genetically predisposed inflammatory and pruritic allergic skin disease with characteristic clinical features associated with immunoglobulin E (IgE) antibodies1.
Allergic contact dermatitis is an inflammatory skin reaction in response to contact with an allergen. This is an immune reaction and requires previous sensitisation to the offending substance2.
Activity of Barazone®
Barazone® contains the active ingredient, budesonide, which exhibits prolonged retention in target tissues making it an ideal choice for the topical treatment of allergic skin disease and allows for a reduced frequency of application. Within the cell, budesonide is reversibly converted to lipophilic esters, which are inactive, and stored intracellularly6. The esters form a reservoir of inactive budesonide within the cell. Over time, these esters are hydrolysed back to reform active budesonide, allowing for prolonged anti-inflammatory activity. This process is known as reversible esterification6.
Barazone® has been shown to reduce the extent and severity of lesions associated with allergic skin disease in dogs. In a study comparing Barazone® to placebo, the lesion scores on dogs treated with Barazone® improved significantly, whereas dogs treated with placebo had deterioration in their lesion scores3. In an additional study, Barazone® significantly improved pruritus in dogs when compared with placebo and overall, it improved the quality of life for these dogs4.
In a randomised, controlled, blinded study, Barazone® demonstrated comparable efficacy to cyclosporine, a widely recognised treatment for the management of canine atopic dermatitis5. There were no detectable differences in CADESI severity scores at any time point assessed. This study showed that Barazone® was comparable to cyclosporine with regards to both reduction in pruritus and lesion scores5.
Due to the topical application and local activity of Barazone®, systemic effects, often seen with oral or systemic corticosteroids, are uncommon.
- Barazone® is a once weekly application.
- Local activity of budesonide within the skin.
- Barazone® is formulated in a leave-on conditioner that is not greasy, will not cause matting of the fur or leave a residue on the coat, meaning it can be easily applied to haired areas of the skin.
- As it is a topical treatment, Barazone® can be used to target affected areas, which will be appropriate in many cases of allergic skin disease. If the lesions are severe and affecting the whole body, however, a maximum dose of 1g/kg once weekly may be used for up to 6 weeks. As with all corticosteroids, the dose should be gradually reduced to the lowest effective dose and frequency to manage the clinical signs.
With allergy season around the corner, Barazone® will play an important role in the multimodal management of canine allergic skin disease.
1. Hensel, P., Santoro, D., Favrot, C., Hill, P., & Griffin, C. (2015). Canine atopic dermatitis: detailed guidelines for diagnosis and allergen identification. BMC veterinary research, 11(1), 1-13.
2. Ho, K. K., Campbell, K. L., & Lavergne, S. N. (2015). Contact dermatitis: a comparative and translational review of the literature. Veterinary dermatology, 26(5), 314-e67.
3. Ahlstrom, L. A., Mason, K. V., & Mills, P. C. (2010). Barazone decreases skin lesions and pruritus and increases quality of life in dogs with atopic dermatitis: a randomized, blinded, placebo controlled trial. Journal of veterinary pharmacology and therapeutics, 33(6), 573-582.
4. Mason, L., A double blinded placebo controlled multicentre clinical field study assessing dose response of 0.0125% budesonide and 0.025% budesonide in a topical leave-in conditioner base, 2011. Commercial in confidence, Dermcare-Vet.
5. Mason, L., A multicentre randomized controlled blinded trial comparing Atopica® (oral cyclosporine) to Barazone® (topical budesonide lotion) for the control of atopy in dogs, 2011. Commercial in confidence, Dermcare-Vet.
6. Brattsand, R., & Miller-Larsson, A. (2003). The role of intracellular esterification in budesonide once-daily dosing and airway selectivity. Clinical therapeutics, 25, C28-C41.